首页> 外文期刊>Breast Cancer: Targets and Therapy >The role of peroxiredoxin II in chemoresistance of breast cancer cells
【24h】

The role of peroxiredoxin II in chemoresistance of breast cancer cells

机译:过氧化物酶Ⅱ在乳腺癌细胞化学耐药中的作用

获取原文
           

摘要

Abstract: Peroxiredoxin (Prx)II belongs to a family of redox-active proteins that use redox-sensitive cysteine in the active site to reduce peroxides. PrxII is induced by various oxidative stimuli and plays an important protective role against oxidative radical damage by reactive oxygen species. PrxII expression levels are correlated with resistance to radiation therapy or certain anti-cancer drugs in radioresistant breast cancer cells, glioblastomas, and head and neck cancer cells as well as in tissue isolated from head and neck patients who do not respond to radiation therapy. Small interfering RNA (siRNA) that inhibits the PrxII gene expression has been shown to partially reverse the radioresistant phenotype in radiation resistant breast cancer cells and sensitizes glioma cells to oxidative stress, highlighting the potential clinical importance of PrxII in radiation resistance in cancer. This article focuses on the role that PrxII may play in chemoresistant breast cancer cells.
机译:摘要:Peroxiredoxin(Prx)II属于氧化还原活性蛋白家族,在活性位点使用氧化还原敏感的半胱氨酸来减少过氧化物。 PrxII由各种氧化刺激诱导,并在抵抗活性氧对氧化自由基的破坏中起重要的保护作用。 PrxII的表达水平与放射线耐药的乳腺癌细胞,胶质母细胞瘤和头颈部癌细胞以及从对放射疗法无反应的头颈部患者分离的组织中的放射治疗或某些抗癌药物的耐药性相关。抑制PrxII基因表达的小干扰RNA(siRNA)已显示出可以部分逆转抗辐射乳腺癌细胞中的放射抗性表型并使胶质瘤细胞对氧化应激敏感,从而突出了PrxII在癌症中抗辐射性方面的潜在临床重要性。本文重点介绍PrxII可能在化学耐药性乳腺癌细胞中发挥的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号